Mexico patent protection granted

October 2019

Mexican patent office grants patent protection for Vigorous Solutions fast-acting sildenafil solutions

China patent protection granted

July 2019

Chinese National Intellectual Property Administration grants patent protection for Vigorous Solutions novel fast-acting sildenafil solutions

Patent protection granted for Eurasian countries

April 2019

Eurasian patent protection for Vigorous Solutions sildenafil solutions is granted in Russia, Turkmenistan, Belarus, Tajikistan, Azerbaijan, Kazakhstan, Kyrgyzstan, and Armenia

Patent granted in Israel

March 2019

Israel Patent Authority issues notice of allowance for Vigorous Solutions novel sildenafil solution products

Second Clinical Trial Completed

January 2019

Second pharmacokinetic (PK) trial in humans is completed, confirming Vigorous Solutions formulation as the fastest absorbed and highest bioavailable Sildenafil product

Second U.S. Patent Granted

December 2018

Vigorous Solutions receives a second U.S. patent allowance, issued to expand the protection of its proprietary liquid sildenafil formulations

First U.S. Patent Granted

May 2018

Vigorous Solutions is issued its first U.S. patent allowance, covering an expansive variety of liquid solutions

European Patent Registration Complete

April 2018

European patent registers Vigorous Solutions product in all 38 European countries

European Patent Allowance

March 2018

Grant Patent issued to Vigorous Solutions by the European Patent Office

First Clinical Trial Completed

January 2018

First pharmacokinetic (PK) trial in humans is completed, confirming Vigorous Solutions formulation’s superiority in time-to-absorption vs Pfizer’s Viagra®.

Patent Granted in South Africa

December 2017

Vigorous Solutions receives a patent allowance in South Africa encompassing a variety of its liquid solutions

$3 Million Seed Funding Round Complete

April 2017

Vigorous Solutions successfully secures $3 Million in seed funding from private investors